Feasibility Study for Collection of HER2 Data by National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program Central Cancer Registries

The clinical importance of human epidermal growth factor receptor-2 (HER2) in breast cancer is now clearly established, given that expression of this tumor marker is used to guide therapy and as a prognostic indicator. Despite its now routine evaluation in breast cancer patients, population-based data are lacking because information on HER2 status is not routinely collected in the majority of population-based cancer registries. We assessed the...